Enovix (NASDAQ:ENVX - Get Free Report) was upgraded by investment analysts at Loop Capital to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports.
Other analysts also recently issued research reports about the company. William Blair downgraded Enovix from an "outperform" rating to a "market perform" rating in a research report on Monday. Wall Street Zen upgraded shares of Enovix from a "strong sell" rating to a "sell" rating in a report on Saturday, May 16th. JPMorgan Chase & Co. downgraded shares of Enovix from a "neutral" rating to an "underweight" rating in a research note on Wednesday, May 6th. Bank of America reiterated a "neutral" rating and set a $5.00 price target on shares of Enovix in a report on Monday. Finally, TD Cowen dropped their price target on shares of Enovix from $7.00 to $5.50 and set a "hold" rating for the company in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $11.77.
View Our Latest Report on Enovix
Enovix Stock Performance
NASDAQ ENVX opened at $3.40 on Monday. The company has a 50-day simple moving average of $5.13 and a two-hundred day simple moving average of $5.78. The company has a quick ratio of 9.37, a current ratio of 9.71 and a debt-to-equity ratio of 2.46. Enovix has a 12-month low of $3.06 and a 12-month high of $14.21. The firm has a market cap of $746.13 million, a price-to-earnings ratio of -4.20 and a beta of 2.32.
Enovix (NASDAQ:ENVX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.02. Enovix had a negative return on equity of 64.50% and a negative net margin of 473.89%.The firm had revenue of $9.02 million for the quarter, compared to analysts' expectations of $8.43 million. During the same period last year, the firm earned ($0.13) earnings per share. The company's revenue for the quarter was up 20.8% compared to the same quarter last year. Enovix has set its Q3 2026 guidance at -0.170--0.130 EPS. On average, equities analysts forecast that Enovix will post -0.78 EPS for the current year.
Hedge Funds Weigh In On Enovix
Several hedge funds have recently made changes to their positions in the business. Private Advisor Group LLC lifted its stake in Enovix by 2.7% in the third quarter. Private Advisor Group LLC now owns 46,519 shares of the company's stock worth $464,000 after acquiring an additional 1,242 shares during the period. Parallel Advisors LLC boosted its holdings in Enovix by 51.9% in the third quarter. Parallel Advisors LLC now owns 3,926 shares of the company's stock valued at $39,000 after acquiring an additional 1,342 shares in the last quarter. Equitable Holdings Inc. increased its position in Enovix by 10.9% during the 3rd quarter. Equitable Holdings Inc. now owns 13,700 shares of the company's stock valued at $137,000 after purchasing an additional 1,342 shares during the period. NewEdge Advisors LLC increased its position in Enovix by 4.7% during the 1st quarter. NewEdge Advisors LLC now owns 41,460 shares of the company's stock valued at $215,000 after purchasing an additional 1,853 shares during the period. Finally, Mariner LLC raised its holdings in Enovix by 3.4% in the 3rd quarter. Mariner LLC now owns 58,343 shares of the company's stock worth $582,000 after purchasing an additional 1,921 shares in the last quarter. 50.92% of the stock is owned by hedge funds and other institutional investors.
Enovix News Roundup
Here are the key news stories impacting Enovix this week:
- Positive Sentiment: Buy upgrade and improving estimates: Zacks upgraded Enovix to Rank #2 (Buy), citing growing optimism about the company’s earnings outlook. Separately, Zacks said ENVX is technically oversold after a steep four-week decline, while analysts have been revising earnings estimates higher—factors that could support a near-term rebound. Enovix upgraded to Buy Why Enovix’s trend might reverse
- Positive Sentiment: CEO transition described as strategic continuity: Enovix said the leadership change is a “CEO transition, not a strategy transition,” reaffirmed its third-quarter 2026 guidance, and reported approximately $552 million in cash. The sizable cash balance may ease near-term financing concerns and support continued development. Enovix CEO transition webcast
- Neutral Sentiment: Unusually high trading activity in Enovix call options indicates elevated speculative interest, but the report does not establish whether investors are positioning for a sustained rally or further volatility. Enovix call option activity
- Negative Sentiment: Analyst downgrade and recent low: William Blair cut ENVX to Market Perform, and the stock recently reached a new 12-month low after the downgrade. Reports also attributed the broader decline in battery-development stocks to sharply higher Treasury yields, which pressure speculative companies. William Blair downgrades Enovix Higher yields pressure speculative growth stocks
Enovix Company Profile
(
Get Free Report)
Enovix Corporation NASDAQ: ENVX develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.
Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Enovix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovix wasn't on the list.
While Enovix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.